Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020

SAN FRANCISCO, U.S. and SUZHOU, China, Nov. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn...

2020-11-11 08:00 6425

Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020

SAN FRANCISCO and SUZHOU, China, Nov. 5, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-11-05 08:00 5626

Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group

SAN FRANCISCO and SUZHOU, China, Oct. 15, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-10-15 08:00 12694

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2020-10-09 19:14 11284

Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period

SAN FRANCISCO and SUZHOU, China, Oct. 7, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-10-07 08:00 13876

Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2020-09-28 12:13 5215

TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2020-09-28 10:15 5841

Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2020-09-21 08:00 7263

Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2020-09-21 08:00 6355

Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2020-09-14 18:00 12634

Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China

SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Inno...

2020-09-03 17:50 4491

Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody

SAN FRANCISCO, and SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2020-09-01 08:00 2207

Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the European Society of Cardiology Annual Conference

SAN FRANCISCO and SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-08-31 08:00 5336

Innovent Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Progress

SAN FRANCISCO, U.S. and SUZHOU, China, Aug. 27, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (...

2020-08-27 09:37 9611

Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement

SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-08-18 18:30 6060

Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China

SUZHOU, China, Aug. 12, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2020-08-12 16:40 7710

Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposium

SUZHOU, China, Aug. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-08-08 21:00 16724

Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody in China

SUZHOU, China, Aug. 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") ...

2020-08-03 08:00 8105

Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China

SUZHOU, China, July 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-07-09 08:00 12001

Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX

SUZHOU, China, June 22, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2020-06-22 07:40 5614